DNA on Demand: New Pacts Push Synthesis Tech to Global Labs

PARIS – March 17, 2026 – French biotech pioneer DNA Script is accelerating a fundamental shift in how scientists access one of biology’s most critical building blocks. The company has announced new distribution agreements that will place its innovative benchtop DNA synthesis platform, SYNTAX, into the hands of researchers across Latin America, South Korea, and Japan.

The partnerships with regional life science distributors Gencell, Bio-Medical Science Co. (BMS), and Biostream are more than a simple business expansion. They represent a significant push to decentralize the production of oligonucleotides—short, single-stranded DNA molecules essential for everything from diagnostics and drug discovery to synthetic biology. This move challenges the decades-old model of centralized, mail-order DNA and promises to slash research timelines for scientists located far from traditional production hubs in the U.S. and Europe.

A New Paradigm for DNA Synthesis

For years, researchers have relied on a handful of large-scale facilities to create custom DNA sequences. This centralized model, while powerful, often introduces significant delays. Scientists place an order and wait days, or even weeks, for the crucial genetic material to be synthesized and shipped, navigating logistical hurdles and potential supply chain disruptions.

The SYNTAX platform aims to dismantle this bottleneck. It is a compact, automated machine—often called a "DNA printer"—that sits directly on a lab bench. Using a proprietary method called Enzymatic DNA Synthesis (EDS), the system allows any researcher to produce high-quality DNA oligos in-house, on-demand, in a matter of hours.

This technology marks a departure from the traditional phosphoramidite chemistry, which involves harsh organic solvents and produces hazardous waste. EDS works in a more biologically friendly aqueous environment, offering superior speed and accuracy, particularly for long or complex sequences that challenge older methods. The result is a faster, more sustainable, and more accessible way to conduct research, effectively democratizing a capability that was once the exclusive domain of specialized providers.

"We’re excited to enter these new partnerships as part of our strategy to scale global accessibility and availability of ssDNA oligos, making them available to researchers anywhere in the world," said Marc Montserrat, Chief Executive Officer of DNA Script, in a statement. He emphasized that the agreements enable researchers to "access oligonucleotides more quickly and reliably, regardless of location."

Fueling Regional Biotech Ecosystems

The strategic selection of Latin America, South Korea, and Japan highlights the transformative potential of localized DNA production. These regions represent diverse and rapidly growing segments of the global biotechnology market, which is projected to grow from around $4 billion today to well over $13 billion within the next decade.

In Latin America, a region with a burgeoning biotech sector expected to exceed $200 billion by 2030, logistical hurdles can be particularly acute. Long shipping times and complex customs for sensitive biological materials can stifle the pace of innovation. By providing local access, DNA Script and its partner Gencell aim to empower regional scientists and support a growing push for biomanufacturing self-sufficiency.

"This alliance represents a fundamental step toward accelerating innovation in Latin America," commented Fabio Andrés Zapata, CEO of Gencell. "By bringing technologies like SYNTAX closer to researchers in the region, we help reduce development times and drive local biomanufacturing."

In East Asia, South Korea and Japan are established powerhouses in advanced research and technology. South Korea's biotech industry is a global force in diagnostics and biopharmaceuticals, while Japan is aggressively investing to become a "land of drug discovery," with a focus on oncology and regenerative medicine. For researchers in these highly competitive environments, speed is paramount. The ability to iterate experiments daily rather than weekly by printing DNA in-house could provide a significant competitive advantage.

Dukhyun Lim, Vice President of Bio-Medical Science, noted that the SYNTAX platform "offers researchers greater control and speed in oligonucleotide production, enabling increased independence and control over project workflows." Echoing this sentiment, Iwabuchi Takeshi, President of BioStream Co. in Japan, added that the partnership helps customers "reduce dependence on overseas synthesis and long delivery timelines."

Building Resilience in a Fragile World

Beyond accelerating individual research projects, the move towards decentralized production carries profound strategic implications for the entire global biotech industry. The COVID-19 pandemic and ongoing geopolitical tensions have exposed the fragility of complex, long-distance supply chains for critical materials, from microchips to medical reagents.

By enabling localized, on-demand manufacturing of DNA, this new model builds inherent resilience into the research and development ecosystem. A lab in São Paulo or Seoul with a benchtop synthesizer is less vulnerable to a shipping shutdown or a trade dispute that could halt a critical project for weeks. It fosters scientific independence and ensures that geography is no longer a primary determinant of scientific speed.

This shift does not eliminate logistics entirely. A new supply chain for the instruments and the specialized enzymatic reagents they consume must be established and maintained. Furthermore, the widespread availability of powerful DNA synthesis technology raises important biosecurity questions, requiring robust technical and regulatory frameworks to prevent misuse.

However, the trend is clear. As the global DNA synthesis market continues its rapid expansion, the ability to produce DNA on-site is becoming less of a novelty and more of a necessity. DNA Script's expansion is a key indicator of a future where the power to write biology is no longer centralized in a few distant factories, but is readily available on lab benches across the world, fueling the next wave of scientific discovery.